Executive Director, Clinical Pharmacology
- Market p25–p75
- $171k–$260k
- Opened · 30d
- +0
- Closed · 30d
- −0
- Opened · 7d
- +1,5276% of open
- All other
- 623,331open
About Us
Kardigan is a heart health company working to make cardiovascular disease preventable, curable and no longer the leading cause of death in the world.
It is Kardigan’s mission to develop multiple targeted treatments in parallel that bring people with cardiovascular diseases to the cures they deserve.
Led by Tassos Gianakakos, Jay Edelberg, M.D., Ph.D., and Bob McDowell, Ph.D., Kardigan’s co-founders have reunited after leading MyoKardia to discover and develop mavacamten, the first cardiac myosin inhibitor, resulting in an acquisition by Bristol Myers Squibb in 2020.
We have a cutting-edge discovery and translational research platform, a pipeline of late-stage candidates, and an industry-leading team that is driven to improve the lives of patients.
At Kardigan, we are motivated by our values which guide how we work, interact, and achieve our goals. Driven by patients and their families, we are deeply committed to improving the lives of patients and prioritizing their needs above all else. We believe in being authentic—leading with truth to bring out the best in others by creating an environment where every person knows they will be fully accepted. With an eagerness to learn, we encourage the highest levels of curiosity and are open to changing our minds. We are committed to winning as a team with urgency, excellence, and intention, and support each other no matter what role we play or where we sit. Lastly, we strive to enable the impossible because patients are counting on us. We are not afraid to take risks to unlock innovation and advance scientific discoveries.
These values are the foundation of our work, empowering us to make a real difference, every day.
About the Job
Job Title: Executive Director, Clinical Pharmacology
Level: Executive Director
Department: Early Development
Hiring Manager: Vice President, Early Development
Location: Princeton, NJ
Classification: Hybrid – On-site 4 days per week (Mon to Thurs)
Job Overview
Reporting to the Vice President, Early Development, the Executive Director, Clinical Pharmacology will provide enterprise-level strategic and scientific leadership for the Clinical Pharmacology function across Kardigan’s cardiovascular development portfolio. This individual will be responsible for defining, establishing, and driving clinical pharmacology strategies from early through late-stage development, supporting regulatory submissions, and serving as the company’s senior clinical pharmacology leader and strategic representative for FDA and other global health authority interactions. This role will partner cross-functionally with senior leaders to shape portfolio priorities, inform critical development decisions, and ensure successful development and registration strategies.
This is a highly visible executive-level leadership position requiring both strategic vision and hands-on execution within a fast-paced, collaborative biotechnology environment. The Executive Director will play a critical role in building and advancing Kardigan’s internal clinical pharmacology capabilities, establishing scientific standards, and ensuring the function effectively supports the company’s long-term pipeline and organizational objectives.
Essential Duties and Responsibilities
- Provide executive-level strategic leadership, functional direction, and operational ownership of the Clinical Pharmacology function, transitioning activities currently supported by external consultants into a sustainable, internally led capability aligned with Kardigan’s portfolio and growth objectives.
- Define, develop, and execute integrated clinical pharmacology strategies across multiple development programs from early phase through late-stage clinical development and regulatory submission, ensuring alignment with portfolio priorities, development milestones, and regulatory objectives.
- Serve as the senior clinical pharmacology leader and primary strategic representative for FDA and other global health authority interactions, including INDs, End-of-Phase meetings, briefing documents, and future NDA submissions, providing scientific leadership and strategic guidance on complex regulatory matters.